Phase II Study of ABT‐122, a Tumor Necrosis Factor– and Interleukin‐17A–Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate

OBJECTIVE: To investigate the safety and efficacy of ABT‐122, a tumor necrosis factor (TNF)– and interleukin‐17A (IL‐17A)–targeted dual variable domain immunoglobulin, in patients with active psoriatic arthritis (PsA) who have experienced an inadequate response to methotrexate. METHODS: Patients (n...

Descripción completa

Detalles Bibliográficos
Autores principales: Mease, Philip J., Genovese, Mark C., Weinblatt, Michael E., Peloso, Paul M., Chen, Kun, Othman, Ahmed A., Li, Yihan, Mansikka, Heikki T., Khatri, Amit, Wishart, Neil, Liu, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221045/
https://www.ncbi.nlm.nih.gov/pubmed/29855175
http://dx.doi.org/10.1002/art.40579

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221045/
https://www.ncbi.nlm.nih.gov/pubmed/29855175
http://dx.doi.org/10.1002/art.40579

Ejemplares similares